Thursday, April 25, 2024 4/25/2024

Development of a next-generation PSD95 Inhibitor for the treatment of acute ische

Award Number: U01NS087876
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

DESCRIPTION (provided by applicant): The mission of NINDS is to reduce the burden of neurological disease. Stroke is a leading cause of mortality and disability, affecting 795,000 people annually in the US at a direct and indirect cost of $38.6 billion. Stroke i a rapidly progressive disorder, with brain damage being near complete by 3 hours after stroke onset. There is a major unmet need for safe stroke treatments to reduce the burden of stroke and improve stroke victims' outcomes. We will address this need by developing an emergency stroke medication that is safe enough to be given to stroke victims in the community even before arrival to a hospital (e.g., by paramedic), or immediately on hospital arrival, thus arresting stroke progression within the first "golden hour" and preferaby no later than 3h after stroke onset. This will be achieved by developing a safe and effective drug that targets neuronal postsynaptic density 95 protein (PSD95), termed a "PSD95 inhibitor". We have already developed a prototype (termed "NA-1") that reduces stroke damage in animals and humans, but that has the side effect of producing hypotension. This makes NA-1 unsuitable for use in emergency situations. To improve on NA-1 we identified 7 potential related candidates. Our objective is to evaluate each in order to select the optimal Lead Candidate for further development in future clinical trials. This will be done through the followin steps: In vitro lead selection: The 7 candidates will be evaluated in vitro for optimal properties that are predictive of efficacy in animal stroke models and for clinical utility; Lad selection in animals: The same candidates will be evaluated in rats for lack of hypotension and then advanced to more detailed animal studies that include evaluations of the drugs' efficacy in experimental strokes. The most effective and safe single candidate will be advanced to the next steps; Manufacturing and formulation studies: The lead PSD95 inhibitor will be manufactured to regulatory (FDA/ICH) standards and used to create a formulation in a drug vial that protects the drug from degrading and that can be used in an ambulance or a hospital; Safety Pharmacology and Toxicity testing. This lead candidate will then be tested in the necessary studies to demonstrate safety in animals, and to confirm that it is appropriate for advancement to a filing of an IND for a Phase 1 human trial. Filing of an IND: The project will culminate with a filing of an IND with the FDA for a Phase 1 human trial. We have already successfully translated NA-1 all the way from its discovery to a successfl phase 2 human clinical trial and are experienced in the process of developing a PSD95 inhibitor and the filing of IND submissions. We are thus confident that this project will provide a safe emergency neuroprotectant for further development in order to reduce the extraordinary burden of stroke on our society.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = -$71,824 )
2020	2017	UNIVERSITY HEALTH NETWORK	200 ELIZABETH ST	TORONTO	ON	M5G 2C4		CAN	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	4	1/25/2020	NON-COMPETING CONTINUATION	-$71,824
														Subtotal = -$71,824

Issue Date FY: 2018 ( Subtotal = $0 )
2018	2017	UNIVERSITY HEALTH NETWORK	200 ELIZABETH ST	TORONTO	ON	M5G 2C4		CAN	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	4	8/2/2018	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $846,905 )
2017	2017	UNIVERSITY HEALTH NETWORK	200 ELIZABETH ST	TORONTO	ON	M5G 2C4		CAN	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	4	9/6/2017	NON-COMPETING CONTINUATION	$846,905
														Subtotal = $846,905

Issue Date FY: 2016 ( Subtotal = $1,198,933 )
2016	2016	UNIVERSITY HEALTH NETWORK	190 Elizabeth Street	TORONTO				CAN	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	9/2/2016	NON-COMPETING CONTINUATION	$1,198,933
														Subtotal = $1,198,933

Issue Date FY: 2015 ( Subtotal = $1,152,717 )
2015	2015	UNIVERSITY HEALTH NETWORK	190 Elizabeth Street	TORONTO				CAN	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	8/17/2015	NON-COMPETING CONTINUATION	$1,152,717
														Subtotal = $1,152,717

Issue Date FY: 2014 ( Subtotal = $573,259 )
2014	2014	UNIVERSITY HEALTH NETWORK	190 Elizabeth Street	TORONTO				CAN	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	9/15/2014	NEW	$573,259
														Subtotal = $573,259

Grand Total All Awards = $3,699,990

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a next-generation PSD95 Inhibitor for the treatment of acute ische

Award Number: U01NS087876

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer